Iniparib，以前命名为BSI-201，是一种静脉给药的PARP1抑制剂，无论是单独使用还是与化疗联合使用，在体外和体内研究中都具有重要的抗肿瘤活性。它对多种培养的癌细胞有活性，包括耐药细胞系。据报道，Iniparib是一种前药，其C-亚硝基代谢物4-碘-3-亚硝基苯甲酰胺通过氧化PARP-1的锌指导致锌排出并抑制PARP活性来选择性杀死肿瘤细胞。

产品性质：

Cas No.：160003-66-7

别名：3-硝基-4-碘苯甲酰胺,BSI201,BSI 201

化学名：4-iodo-3-nitrobenzamide

Canonical SMILES：C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I

分子式：C7H5IN2O3

分子量：292.03

溶解度：≥ 103.4 mg/mL in DMSO, ≥ 24.3 mg/mL in EtOH with ultrasonic and warming

储存条件：Store at -20°C

注意事项：

为了您的安全和健康，请穿实验服并戴一次性手套操作。

References：

[1].Liang H, Tan AR. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs. 2010 Sep;13(9):646-56.

[2].Xuesong Liu, Yan Shi, David X. Maag, Joann P. Palma, Melanie J. Patterson, Paul A. Ellis, Bruce W. Surber, Damien B. Ready, Niru B. Soni, Uri S. Ladror, Allison J. Xu, Ramesh Iyer, John E. Harlan, Larry R. Solomon, Cherrie K. Donawho, Thomas D. Penning, Eric F. Johnson, Alexander R. Shoemaker. Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor. Clinical Cancer Research. January 15, 2012 18; 510.

[3].S. Kopetz, M. M. Mita, I. Mok, K. K. Sankhala, J. Moseley, B. M. Sherman, C. R. Bradley and A. W. Tolcher. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. Journal of Clinical Oncology. (Meeting Abstracts) May 2008 vol. 26 no. 15_suppl 3577